Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Tevard Biosciences, Inc., a biotechnology company at the forefront of developing tRNA-based therapies for genetic diseases, has announced the appointment of Dr. Elisabeth Gardiner as its new Chief Scientific Officer. With over 25 years of experience in drug discovery and development, Dr. Gardiner's leadership is expected to accelerate the company's mission to create durable treatments targeting the root causes of genetic disorders.
Dr. Gardiner's role will focus on advancing Tevard's innovative platform of engineered suppressor tRNAs, which have shown promise in restoring full-length dystrophin in models of Duchenne Muscular Dystrophy (DMD). Her extensive background in biotech and pharmaceuticals, including contributions to 11 IND filings and the advancement of five therapies into clinical trials, positions her as a key figure in Tevard's next phase of growth.
The significance of this appointment lies in the potential of tRNA-based therapies to address limitations of conventional gene therapy, such as the challenges posed by large genes and the need for mutation-specific corrections. Tevard's approach, which enables precise and durable protein restoration, offers hope for treating a wide range of genetic diseases with a limited number of suppressor tRNAs.
Recent preclinical data from Tevard has demonstrated the efficacy of its tRNA-based therapeutic in restoring dystrophin protein expression and improving motor function in a DMD mouse model, without adverse effects. This breakthrough underscores the transformative potential of tRNA-based therapies for patients with diseases that have been difficult to treat with traditional methods.
As Tevard progresses with its lead program targeting TTN-related dilated cardiomyopathy and continues preclinical work in Dravet syndrome and other developmental and epileptic encephalopathies, the appointment of Dr. Gardiner signals a strong commitment to advancing these innovative treatments. Her expertise and patient-centered approach align with Tevard's goals, offering new possibilities for patients with rare genetic diseases.